The estimated Net Worth of Inc. Innoviva, is at least $42.6 millió dollars as of 1 September 2020. Inc Innoviva owns over 4,672,897 units of Armata Pharmaceuticals Inc stock worth over $42,574,205 and over the last 10 years Inc sold ARMP stock worth over $0.
Sign up
Inc Innoviva ARMP stock SEC Form 4 insiders trading
Inc has made over 3 trades of the Armata Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Inc bought 4,672,897 units of ARMP stock worth $12,523,364 on 1 September 2020.
The largest trade Inc's ever made was buying 12,677,490 units of Armata Pharmaceuticals Inc stock on 11 June 2020 worth over $31,693,725. On average, Inc trades about 6,267,012 units every 40 days since 2014. As of 1 September 2020 Inc still owns at least 18,672,897 units of Armata Pharmaceuticals Inc stock.
You can see the complete history of Inc Innoviva stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Inc Innoviva's mailing address?
Inc's mailing address filed with the SEC is 1350 OLD BAYSHORE HIGHWAY SUITE 400, , BURLINGAME, CA, 94010.
Insiders trading at Armata Pharmaceuticals Inc
Over the last 5 years, insiders at Armata Pharmaceuticals Inc have traded over $0 worth of Armata Pharmaceuticals Inc stock and bought 24,083,630 units worth $91,149,692 . The most active insiders traders include Inc.Innoviva Strategic Oppo..., Inc. Innoviva, és Michael S Perry. On average, Armata Pharmaceuticals Inc executives and independent directors trade stock every 122 days with the average trade being worth of $9,151,779. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 31 March 2022, trading 5,385,208 units of ARMP stock currently worth $26,926,040.
What does Armata Pharmaceuticals Inc do?
c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
What does Armata Pharmaceuticals Inc's logo look like?
Complete history of Inc Innoviva stock trades at Theravance Biopharma Inc, Entasis Therapeutics Inc és Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc executives and stock owners
Armata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Todd R. Patrick MBA,
Advisor & Director -
Dr. Brian Varnum Ph.D.,
CEO & Director -
Steven R. Martin,
Chief Financial Officer -
Robin Kramer,
Director -
Mina Pastagia,
Vice President - Clinical Development -
Sarah Schlesinger,
Director -
Odysseas Kostas,
Director -
Todd Peterson,
Director -
Heather Jones,
Medical Director -
Joseph Patti,
Director -
Richard Bastiani,
Director -
Duane Morris,
Vice President - Operations -
Igor Bilinsky,
Chief Operating Officer, Senior Vice President -
Steven Martin,
Chief Financial Officer -
Todd Patrick,
Chief Executive Officer, Director -
Brian Varnum,
President, Chief Development Officer -
Erin Butler,
VP of Fin. & Admin. -
Dr. Mina Pastagia M.D., MS,
Sr. VP of Clinical Devel. -
Duane Alfred Morris BA,
VP of Operations -
Dr. Wenyuan Shi Ph.D.,
Co-Founder & Founding Scientist -
Deborah Birx,
Chief Executive Officer -
Richard Rychlik,
Corporate Controller and PFO -
Inc. Innoviva,,
10% owner -
Richard Bear,
Director -
Michael S Perry,
Director -
H Stewart Parker,
Director -
Jeremy Curnock Cook,
Director -
Inc.Innoviva Strategic Oppo...,
-
Jules Haimovitz,
Director